 |
|
|
| |
Addressing Barriers to HCV Elimination in Italy: Health Care Resource Utilization and Cost Savings From Using 8 vs 12 Weeks of Glecaprevir/Pibrentasvir Therapy
|
| |
| |
AASLD 2020 Nov 11-16 virtual
Reported by Jules Levin
Massimo Andreoni1, Giovanni Di Perri2, Marcello Persico3, Andrea Marcellusi4, Olivier Ethgen5,6, Yuri Sanchez Gonzalez7, Mark Bondin7, Zhenzhen Zhang7, Antonella De Michina8, Rocco Cosimo Damiano Merolla8, Antonio Craxì91University of Tor Vergata, Rome, Italy; 2Department of Clinical Infectious Diseases, University of Turin, Turin, Italy; 3Internal Medicine and Hepatology Unit, Department of Medicine and Surgery "Scuola Medica Salernitana," University of Salerno, Baronissi, Italy; 4Center for Economic and International Studies, Faculty of Economics, University of Tor Vergata, Rome, Italy; 5SERFAN Innovation, Namur, Belgium; 6Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium; 7AbbVie Inc., North Chicago, Illinois, United States; 8AbbVie S.r.l., Rome, Italy; 9GI and Liver Unit, PROMISE, University of Palermo, Palermo, Italy
|
| |
|
|
|
|
|
